See more : Enel Generación Costanera S.A. (EDCFF) Income Statement Analysis – Financial Results
Complete financial analysis of MaaT Pharma SA (MAAT.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MaaT Pharma SA, a leading company in the Biotechnology industry within the Healthcare sector.
- Somi Conveyor Beltings Limited (SOMICONVEY.NS) Income Statement Analysis – Financial Results
- Nuveen Municipal Value Fund, Inc. (NUV) Income Statement Analysis – Financial Results
- Leo Holdings Corp. II Redeemabl (LHC-WT) Income Statement Analysis – Financial Results
- Tupy S.A. (TUPY3.SA) Income Statement Analysis – Financial Results
- M&A Capital Partners Co.,Ltd. (6080.T) Income Statement Analysis – Financial Results
MaaT Pharma SA (MAAT.PA)
About MaaT Pharma SA
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.23M | 1.43M | 972.00K | 0.00 | 89.30K | 892.00K | 109.32K |
| Cost of Revenue | 573.00K | 339.00K | 166.00K | 164.00K | 97.00K | 79.00K | 3.50M |
| Gross Profit | 1.66M | 1.09M | 806.00K | -164.00K | -7.70K | 813.00K | -3.39M |
| Gross Profit Ratio | 74.28% | 76.29% | 82.92% | 0.00% | -8.62% | 91.14% | -3,102.25% |
| Research & Development | 20.30M | 14.48M | 9.15M | 6.10M | 5.27M | 4.51M | 0.00 |
| General & Administrative | 2.55M | 1.47M | 1.17M | 1.29M | 922.00K | 787.00K | 0.00 |
| Selling & Marketing | 449.00K | 347.00K | 217.00K | 99.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 3.00M | 1.81M | 1.38M | 1.29M | 922.00K | 787.00K | 1.27M |
| Other Expenses | -1.70M | -1.64M | -830.00K | -2.14M | -1.23M | -892.00K | 0.00 |
| Operating Expenses | 21.29M | 14.65M | 9.70M | 5.25M | 4.97M | 4.40M | 1.32M |
| Cost & Expenses | 22.17M | 14.99M | 9.87M | 5.25M | 4.97M | 4.40M | 4.82M |
| Interest Income | 639.00K | 45.00K | 121.00K | 45.00K | 66.25K | 0.00 | 73.23K |
| Interest Expense | 402.00K | 185.00K | 121.00K | 45.00K | 20.00K | 71.00K | 0.00 |
| Depreciation & Amortization | 871.00K | 429.00K | 328.00K | 164.00K | 97.00K | 79.00K | 51.20K |
| EBITDA | -19.74M | -13.32M | -8.71M | -6.58M | -6.76M | -5.09M | -4.66M |
| EBITDA Ratio | -886.00% | -916.01% | -881.69% | 0.00% | -5,536.15% | -484.87% | -4,259.74% |
| Operating Income | -19.94M | -13.56M | -8.89M | -5.25M | -4.97M | -4.40M | -4.71M |
| Operating Income Ratio | -895.11% | -947.97% | -914.92% | 0.00% | -5,559.66% | -493.72% | -4,306.57% |
| Total Other Income/Expenses | 226.00K | -156.00K | -126.00K | -49.00K | -879.00K | -71.00K | -73.28K |
| Income Before Tax | -19.72M | -13.71M | -9.02M | -5.30M | -5.84M | -4.48M | -4.78M |
| Income Before Tax Ratio | -884.96% | -958.95% | -927.88% | 0.00% | -6,543.94% | -501.68% | -4,373.60% |
| Income Tax Expense | 0.00 | 157.00K | 121.00K | 49.00K | 803.00K | 71.00K | 922.81K |
| Net Income | -19.72M | -13.87M | -9.14M | -5.35M | -6.65M | -4.55M | -3.86M |
| Net Income Ratio | -884.96% | -969.93% | -940.33% | 0.00% | -7,443.12% | -509.64% | -3,529.47% |
| EPS | -1.73 | -1.40 | -3.77 | -25.91 | -32.20 | -4.40 | 0.00 |
| EPS Diluted | -1.73 | -1.40 | -3.77 | -25.91 | -32.20 | -4.40 | 0.00 |
| Weighted Avg Shares Out | 11.37M | 9.89M | 2.43M | 206.46K | 206.46K | 1.03M | 0.00 |
| Weighted Avg Shares Out (Dil) | 11.37M | 9.89M | 2.43M | 206.46K | 206.46K | 1.03M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports